Skip to main content
Top
Published in: Cancer Causes & Control 5/2017

01-05-2017 | Original paper

Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium

Authors: Jennifer Ose, Helena Schock, Elizabeth M. Poole, Matti Lehtinen, Kala Visvanathan, Kathy Helzlsouer, Julie E. Buring, I-Min Lee, Anne Tjønneland, Marie-Christine Boutron-Ruault, Antonia Trichopoulou, Amalia Mattiello, N. Charlotte Onland-Moret, Elisabete Weiderpass, María-José Sánchez, Annika Idahl, Ruth C. Travis, Sabina Rinaldi, Melissa A. Merritt, Nicolas Wentzensen, Shelley S. Tworoger, Rudolf Kaaks, Renée T. Fortner

Published in: Cancer Causes & Control | Issue 5/2017

Login to get access

Abstract

Purpose

Biologic evidence suggests that the Insulin-like growth factor (IGF)-family may be involved in the etiology of epithelial invasive ovarian cancer (EOC). However, prospective studies investigating the role of IGF-I in ovarian carcinogenesis have yielded conflicting results.

Methods

We pooled and harmonized data from 6 case–control studies nested within the Ovarian Cancer Cohort Consortium to investigate the association between pre-diagnosis IGF-I concentrations and subsequent risk of EOC. We evaluated IGF-I concentrations and risk of EOC overall and by tumor subtype (defined by histology, grade, stage) in 1,270 cases and 2,907 matched controls. Multivariable conditional logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI).

Results

Doubling of IGF-I concentration was associated with significantly lower risk of overall EOC [ORlog2 = 0.82; CI 0.72–0.93]. We observed no heterogeneity by tumor characteristics (e.g., histology, p het = 0.62), menopausal status at blood collection (p het = 0.79), or age at diagnosis (p het = 0.60).

Conclusions

These results suggest that IGF-I concentrations are inversely associated with EOC risk, independent of histological phenotype. Future prospective research should consider potential mechanisms for this association, including, considering other members of the IGF-family to better characterize the role of IGF-signaling in the etiology of EOC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bruchim I, Werner H (2013) Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets 17:307–320CrossRefPubMed Bruchim I, Werner H (2013) Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets 17:307–320CrossRefPubMed
2.
go back to reference Shen MR, Lin AC, Hsu YM et al (2004) Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J Biol Chem 279:40017–40025CrossRefPubMed Shen MR, Lin AC, Hsu YM et al (2004) Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J Biol Chem 279:40017–40025CrossRefPubMed
3.
go back to reference Alsina-Sanchis E, Figueras A, Lahiguera A et al (2016) The TGFbeta pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. Int J Cancer 139:1894–1903CrossRefPubMed Alsina-Sanchis E, Figueras A, Lahiguera A et al (2016) The TGFbeta pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. Int J Cancer 139:1894–1903CrossRefPubMed
4.
go back to reference Lukanova A, Lundin E, Toniolo P et al (2002) Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 101:549–554CrossRefPubMed Lukanova A, Lundin E, Toniolo P et al (2002) Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 101:549–554CrossRefPubMed
5.
go back to reference Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE (2007) Insulin-like growth factors and ovarian cancer risk: a nested case–control study in three cohorts. Cancer Epidemiol Biomark Prev 16:1691–1695CrossRef Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE (2007) Insulin-like growth factors and ovarian cancer risk: a nested case–control study in three cohorts. Cancer Epidemiol Biomark Prev 16:1691–1695CrossRef
6.
go back to reference Peeters PH, Lukanova A, Allen N et al (2007) Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 14:81–90CrossRefPubMed Peeters PH, Lukanova A, Allen N et al (2007) Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 14:81–90CrossRefPubMed
7.
go back to reference Ose J, Fortner RT, Schock H et al (2015) Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer 112:162–166CrossRefPubMed Ose J, Fortner RT, Schock H et al (2015) Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer 112:162–166CrossRefPubMed
8.
go back to reference Schock H, Fortner RT, Surcel HM et al (2015) Early pregnancy IGF-I and placental GH and risk of epithelial ovarian cancer: a nested case–control study. Int J Cancer 137:439–447CrossRefPubMed Schock H, Fortner RT, Surcel HM et al (2015) Early pregnancy IGF-I and placental GH and risk of epithelial ovarian cancer: a nested case–control study. Int J Cancer 137:439–447CrossRefPubMed
9.
go back to reference Wentzensen N, Poole EM, Trabert B et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 34:2888–2898 Wentzensen N, Poole EM, Trabert B et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 34:2888–2898
10.
11.
12.
13.
go back to reference Beberashvili I, Sinuani I, Azar A et al (2013) Decreased IGF-1 levels potentiate association of inflammation with all-cause and cardiovascular mortality in prevalent hemodialysis patients. Growth Horm IGF Res 23:209–214CrossRefPubMed Beberashvili I, Sinuani I, Azar A et al (2013) Decreased IGF-1 levels potentiate association of inflammation with all-cause and cardiovascular mortality in prevalent hemodialysis patients. Growth Horm IGF Res 23:209–214CrossRefPubMed
14.
go back to reference Savastano S, Di Somma C, Pizza G et al (2011) Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. J Transl Med 9:136CrossRefPubMedPubMedCentral Savastano S, Di Somma C, Pizza G et al (2011) Liver-spleen axis, insulin-like growth factor-(IGF)-I axis and fat mass in overweight/obese females. J Transl Med 9:136CrossRefPubMedPubMedCentral
15.
go back to reference Ose J, Schock H, Tjonneland A et al (2015) Inflammatory markers and risk of epithelial ovarian cancer by tumor subtypes: the EPIC cohort. Cancer Epidemiol Biomarkers Prev 24:951–961CrossRefPubMedPubMedCentral Ose J, Schock H, Tjonneland A et al (2015) Inflammatory markers and risk of epithelial ovarian cancer by tumor subtypes: the EPIC cohort. Cancer Epidemiol Biomarkers Prev 24:951–961CrossRefPubMedPubMedCentral
16.
go back to reference Poole EM, Lee IM, Ridker PM, Buring JE, Hankinson SE, Tworoger SS (2013) A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor alpha receptor 2 levels and risk of ovarian cancer. Am J Epidemiol 178:1256–1264CrossRefPubMedPubMedCentral Poole EM, Lee IM, Ridker PM, Buring JE, Hankinson SE, Tworoger SS (2013) A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor alpha receptor 2 levels and risk of ovarian cancer. Am J Epidemiol 178:1256–1264CrossRefPubMedPubMedCentral
17.
go back to reference Trabert B, Pinto L, Hartge P et al (2014) Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol 135:297–304CrossRefPubMedPubMedCentral Trabert B, Pinto L, Hartge P et al (2014) Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol 135:297–304CrossRefPubMedPubMedCentral
18.
go back to reference McSorley MA, Alberg AJ, Allen DS et al (2007) C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109:933–941CrossRefPubMed McSorley MA, Alberg AJ, Allen DS et al (2007) C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109:933–941CrossRefPubMed
19.
go back to reference Lundin E, Dossus L, Clendenen T et al (2009) C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 20:1151–1159CrossRefPubMedPubMedCentral Lundin E, Dossus L, Clendenen T et al (2009) C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 20:1151–1159CrossRefPubMedPubMedCentral
20.
go back to reference Clapp JF 3rd, Schmidt S, Paranjape A, Lopez B (2004) Maternal insulin-like growth factor-I levels (IGF-I) reflect placental mass and neonatal fat mass. Am J Obstet Gynecol 190:730–736CrossRefPubMed Clapp JF 3rd, Schmidt S, Paranjape A, Lopez B (2004) Maternal insulin-like growth factor-I levels (IGF-I) reflect placental mass and neonatal fat mass. Am J Obstet Gynecol 190:730–736CrossRefPubMed
21.
go back to reference Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N (2002) Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin Chem 48:2248–2251PubMed Borofsky ND, Vogelman JH, Krajcik RA, Orentreich N (2002) Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin Chem 48:2248–2251PubMed
Metadata
Title
Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium
Authors
Jennifer Ose
Helena Schock
Elizabeth M. Poole
Matti Lehtinen
Kala Visvanathan
Kathy Helzlsouer
Julie E. Buring
I-Min Lee
Anne Tjønneland
Marie-Christine Boutron-Ruault
Antonia Trichopoulou
Amalia Mattiello
N. Charlotte Onland-Moret
Elisabete Weiderpass
María-José Sánchez
Annika Idahl
Ruth C. Travis
Sabina Rinaldi
Melissa A. Merritt
Nicolas Wentzensen
Shelley S. Tworoger
Rudolf Kaaks
Renée T. Fortner
Publication date
01-05-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 5/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0852-8

Other articles of this Issue 5/2017

Cancer Causes & Control 5/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine